134 related articles for article (PubMed ID: 36588105)
1. Co-targeting BCL-X
Khan S; Kellish P; Connis N; Thummuri D; Wiegand J; Zhang P; Zhang X; Budamagunta V; Hua N; Yang Y; De U; Jin L; Zhang W; Zheng G; Hromas R; Hann C; Zajac-Kaye M; Kaye FJ; Zhou D
Cell Death Discov; 2023 Jan; 9(1):1. PubMed ID: 36588105
[TBL] [Abstract][Full Text] [Related]
2. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
3. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
4. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
bioRxiv; 2024 Mar; ():. PubMed ID: 38464204
[TBL] [Abstract][Full Text] [Related]
5. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
Jaiswal A; Jaiswal A; Williamson EA; Gelfond J; Zheng G; Zhou D; Hromas R
Cancer Chemother Pharmacol; 2023 Jan; 91(1):89-95. PubMed ID: 36346454
[TBL] [Abstract][Full Text] [Related]
6. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X
Thummuri D; Khan S; Underwood PW; Zhang P; Wiegand J; Zhang X; Budamagunta V; Sobh A; Tagmount A; Loguinov A; Riner AN; Akki AS; Williamson E; Hromas R; Vulpe CD; Zheng G; Trevino JG; Zhou D
Mol Cancer Ther; 2022 Jan; 21(1):184-192. PubMed ID: 34667112
[TBL] [Abstract][Full Text] [Related]
8. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
9. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
10. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
11. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
12. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S
J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
14. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
[TBL] [Abstract][Full Text] [Related]
15. Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors.
Senichkin VV; Pervushin NV; Zamaraev AV; Sazonova EV; Zuev AP; Streletskaia AY; Prikazchikova TA; Zatsepin TS; Kovaleva OV; Tchevkina EM; Zhivotovsky B; Kopeina GS
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008345
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells.
Abdul Rahman SF; Azlan A; Lo KW; Azzam G; Mohana-Kumaran N
Discov Oncol; 2022 Feb; 13(1):9. PubMed ID: 35201512
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.
Seyfried F; Stirnweiß FU; Niedermayer A; Enzenmüller S; Hörl RL; Münch V; Köhrer S; Debatin KM; Meyer LH
Leukemia; 2022 Apr; 36(4):901-912. PubMed ID: 35031695
[TBL] [Abstract][Full Text] [Related]
18. Co-operation of MCL-1 and BCL-X
Galas-Filipowicz D; Chavda SJ; Gong JN; Huang DCS; Khwaja A; Yong K
Front Oncol; 2024; 14():1394393. PubMed ID: 38651147
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
Ohtsu A; Arai S; Sawada T; Kato M; Maeno Y; Miyazawa Y; Fujizuka Y; Sekine Y; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2022 Nov; 628():76-83. PubMed ID: 36084554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
